RVMD Q1 2020 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$19B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M-12.3% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$21M-182.6% margin

Net Income

-$20M-169.1% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

-4.5%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$454M

Total Liabilities

$69M

Stockholders' Equity

$385M

Cash & Equivalents

$183M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$13M	-12.3%
Gross Profit	$12M	$13M	-12.3%
Operating Income	-$21M	-$10M	-102.0%
Net Income	-$20M	-$10M	-92.7%

Revenue Segments

Collaboration Revenue Related Party

$12M100%